$3.09
24.60% day before yesterday
Nasdaq, Dec 27, 10:04 pm CET
ISIN
US19188J3005
Symbol
COCP
Sector
Industry

Cocrystal Pharma Inc Stock price

$3.09
+0.99 47.14% 1M
+0.54 21.18% 6M
+1.37 79.42% YTD
+1.33 75.57% 1Y
-5.20 62.74% 3Y
-2.28 42.46% 5Y
-155.31 98.05% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+0.61 24.60%
ISIN
US19188J3005
Symbol
COCP
Sector
Industry

Key metrics

Market capitalization $31.44m
Enterprise Value $20.22m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.47
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-20.31m
Free Cash Flow (TTM) Free Cash Flow $-15.38m
Cash position $13.10m
EPS (TTM) EPS $-1.84
P/E forward negative
Short interest 0.03%
Show more

Is Cocrystal Pharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Cocrystal Pharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Cocrystal Pharma Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Cocrystal Pharma Inc:

Buy
100%

Financial data from Cocrystal Pharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.10 0.10
76% 76%
-
- -
-
-
- Selling and Administrative Expenses 5.45 5.45
9% 9%
-
- Research and Development Expense 15 15
4% 4%
-
-22 -22
12% 12%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -20 -20
2% 2%
-
Net Profit -19 -19
4% 4%
-

In millions USD.

Don't miss a Thing! We will send you all news about Cocrystal Pharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cocrystal Pharma Inc Stock News

Neutral
GlobeNewsWire
4 months ago
BOTHELL, Wash., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc .'s (Nasdaq: COCP) management announces its participation in the upcoming Virtual Investor Summit Microcap Forum in August and the H.C. Wainwright 26th Annual Global Investment Conference in September.
Neutral
Accesswire
5 months ago
NEW YORK, NY / ACCESSWIRE / August 15, 2024 / CoCrystal Pharma (NASDAQ:COCP), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses and noroviruses, announces that management will present a company overview at the virtual Investor Summit Microcap Forum being held Tuesday, August 20, ...

Company Profile

Cocrystal Pharma, Inc. is a biotechnology company, which engages in the discovery and development of novel antiviral therapeutics. It focuses on the preclinical and early clinical stage antiviral compounds for unmet medical needs including influenza, Hepatitis C virus, and norovirus infections. The company was founded on January 2, 2014 and is headquartered in Bothell, WA.

Head office United States
CEO Sam Lee
Employees 12
Founded 2008
Website www.cocrystalpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today